Frontier Science collaborated with Janssen Actelion on the TOMORROW trial. The study assessed the efficacy, safety and pharmacokinetics of macitentan (Opsumit®) versus standard of care in children with pulmonary arterial hypertension (PAH).
Frontier Science (Scotland) Ltd worked on the output development and led statistical programming up to the dummy run preparing for formal protocol analyses. FSS was responsible for routine reporting and continues to be responsible for aggregate outputs for the Independent Data Monitoring Committee Open Session meetings. The statistical team in the Frontier Science Foundation office in Madison WI is a separate, firewalled, statistical unit providing unblinded statistical analysis for the IDMC.